期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 258, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2023.115616
关键词
Innate immunity; Inflammation; IRAK4 inhibitor; Pharmacokinetics; dihydrofuro[2; b ]pyridine
In this study, a series of IRAK4 inhibitors based on a dihydrofuro[2,3-b]pyridine scaffold were developed. Compound 38 showed improved clearance and excellent biochemical potency against IRAK4. It also demonstrated efficacy in inhibiting pro-inflammatory cytokines and showed potential for the treatment of inflammatory and autoimmune disorders.
Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key regulator to control downstream NF-KB and MAPK signals in the innate immune response and has been proposed as a therapeutic target for the treatment of inflammatory and autoimmune diseases. Herein, a series of IRAK4 inhibitors based on a dihydrofuro[2,3-b]pyridine scaffold was developed. Structural modifications of the screening hit 16 (IC50 = 243 nM) led to IRAK4 inhibitors with improved potency but high clearance (Cl) and poor oral bioavailability, as exemplified by compound 21 (IC50 = 6.2 nM, Cl = 43 ml/min/kg, F = 1.6%, LLE = 5.4). Structure modification aimed at improving LLE and reducing clearance identified compound 38. Compound 38 showed significantly improved clearance while maintained excellent biochemical potency against IRAK4 (IC50 = 7.3 nM, Cl = 12 ml/min/kg, F = 21%, LLE = 6.0). Importantly, compound 38 had favorable in vitro safety and ADME profiles. Furthermore, compound 38 reduced the in vitro production of pro-inflammatory cytokines in both mouse iBMDMs and human PBMCs and was orally efficacious in the inhibition of serum TNF-& alpha; secretion in LPS-induced mouse model. These findings suggested that compound 38 has development potential as an IRAK4 inhibitor for the treatment of inflammatory and autoimmune disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据